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Conclusion:There is an increased risk of venous thrombosis in patients
with cancer. The risk is greatest in the first few months after diagnosis and in
the presence of distal metastasis. Patients also with factor V Leiden and
prothrombin 20210A mutations have an even higher risk.
Summary: This is a report of the Multiple Environmental and Genetic
Assessment (MEGA) of Risk Factors for Venous Thrombosis Study. MEGA
is a case-controlled, population-based study evaluating the risk of venous
thrombosis with various risk factors. This report details risk of venous
thrombosis with cancer and the joint effects of cancer and selected genetic
mutations predisposing to venous thrombosis.
Patients were identified at six anticoagulation clinics in The Nether-
lands between March 1, 1999, and May 31, 2002. Patients included were
those 18 to 70 years of age with a first-time diagnosis of pulmonary
embolism or lower extremity deep venous thrombosis. Control patients
(partners of the patients with venous thrombosis) were also used in the
study. Both patients and controls received a questionnaire to evaluate
acquired risk factors for venous thrombosis. Once anticoagulation therapy
had been discontinued for 3 months, the patients and controls were inter-
viewed and blood was taken for analysis of factor V Leiden and prothrombin
20210A mutations.
In patients with malignancy, the overall risk of venous thrombosis was
increased seven times (odds ratio [OR], 6.7; 95% confidence interval [CI],
5.2 to 8.6). The highest risk was present in patients with hematologic
malignancies (OR, 28.0; 95% CI, 4.0 to 199.7). Risk was also substantially
increased in patients with gastrointestinal cancers (OR, 18.9; 95% CI, 4.6 to
77.8), and patients with pulmonary malignancies (OR, 24.8; 95% CI, 3.4 to
181.1). Risk was highest in the first several months after a malignancy
diagnosis (adjusted OR, 53.5; 95% CI, 8.6 to 334.3). In patients with
cancer, the presence of distal metastatic disease further increased the risk of
venous thromboembolism (VTE) compared with patients without meta-
static disease (adjusted OR, 19.8; 95% CI, 2.6 to 149.1). The combination
of cancer and factor V Leiden mutation increased the risk of VTE 12 times
compared with patients with factor V Leiden mutation and no diagnosed
malignancy. Results were similar for patients with and without cancer with
respect to the prothrombin 20210A mutation.
Comment: The data raise the question of whether patients with cancer
should be screened for factor V Leiden and prothrombin 20210A mutation
and treated with prophylactic anticoagulation therapy if a mutation is
present. Also the question arises of whether prophylactic anticoagulation is
indicated in patients with malignancies associated with an especially high risk
for VTE. The cost-effectiveness of such strategies and their ultimate ability
to prolong life or improve quality of life is clear in patients with cancer who
are undergoing surgery or active chemotherapy (Acta Haematol 2001;106:
73-80). There are currently no data to suggest that routine prophylaxis for
VTE in all cancer patients would be effective. However, the results of the
current study suggest certain subgroups of patients with cancer should be
studied more closely for potential benefit of routine VTE prophylaxis.
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